Roivant Sciences Ltd.
ROIV
Rank in Stocks
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Share Price
$33.73
Last synced: 2026-07-31
Market Cap
$24.37B
Change (1 day)
-2.28%
Change (1 year)
90.15%
Country
GB
Trade Roivant Sciences Ltd. (ROIV)
Category
Healthcare
P/S ratio for Roivant Sciences Ltd. (ROIV)
P/S ratio as of October 2026 TTM: 3.22K
According to Roivant Sciences Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.22K. At the end of 2024 the company had a P/S ratio of 65.46.
P/S ratio history for Roivant Sciences Ltd. from 2020 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.22K | 1,179.79% |
| 2025 | 251.93 | 284.85% |
| 2024 | 65.46 | -23.74% |
| 2023 | 85.84 | 43.44% |
| 2022 | 59.84 | -78.74% |
| 2021 | 281.46 | 167.51% |
| 2020 | 105.21 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | -99.69% |
US
|
|
| 40.55 | -98.74% |
US
|
|
| 3.96 | -99.88% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.69% |
NL
|
